终末期肾病继发Xp11.2易位/TFE3基因融合相关性肾癌1例及文献复习
摘要
Xp11.2易位/TFE3基因融合相关性肾癌是临床少见的一种肾癌亚型,多发于青少年。终末期肾病的发病机理尚未阐明,与免疫功能障基础上癌基因激活和DNA修复能力下降均有一定关系。TFE3免疫组化阳性是诊断此类肾癌的关键依据。腹腔镜下根治性患肾切除术是终末期肾病相关性肾癌较理想的手术治疗方式,围术期可采用小剂量低分子肝素化血透。
引文
[1]Butler AM,Olshan AF,Kshirsagar AV,et al. Cancer Incidence Among US Medicare ESRD Patients Receiving Hemodialysis,1996-2009[J]. Am JKidney Dis,2015,65(5):763-772.
[2]Jong B,Molenaar IM,Leeuw JA,et al. Cytogenetics of a renal adenocarcinoma in a 2-year-old child[J]. Cancer Genet Cytogenet,1986,21(2):165-169.
[3]朱冠辰,宋剑楠,连惠波.长期血液透析的终末期肾病患者合并肾癌二例[J].江苏医药,2015,41(5):600-601.
[4]朱文芳,何建强,巢军,等.枸橼酸?无肝素和低分子肝素抗凝在血液透析中的应用评价[J].临床医学,2015,5(35):39-41.
[5]施向东.枸橼酸抗凝在血液透析中的应用[J].中国中西医结合肾病杂志,2007,8(5):286-287.
[6]Tolwani A,Wille KM. Advances in continuous renal replacement therapy:citrate anticoagulation update[J]. Blood Purif,2012,34(2):88-93.
[7]Yamashita K,Ito F,Nakazawa H. Perioperative outcomes of laparoscopic radical nephrectmy for renal ceysis-dependent end-stsge renal disease[J]. Ther Apher Dial,2012,16(3):254-259.
[8]Argani P,Lal P,Hutchinson B,et al. Aberrant nuclear Immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions:a sensitive and specific immunohistochemical assay[J]. Am J Surg Pathol,2003,27(6):750-761.
[9]陈显成,甘卫东,郭宏骞. Xp11.2易位/TFE3基因融合相关性肾癌:一种需要更多认识的肾癌亚型[J].中华临床医师杂志(电子版),2014,8(21):3749-3752.
[10]鲁勤波,高艳青.腹膜透析和血液透析对终末期肾病患者免疫功能的对比研究[J].中国中西医结合肾病杂志,2015,16(3):249-251.
[11]Scherer A,Gunther OP,Balshaw RF,et al. Alteration of human blood cell transcriptome in uremia[J]. BMC Medical Genomics,2013,6(1):1755-1767.
[12]Shaheen M,Allen C,Nickoloff J A,et al. Synthetic lethality:exploiting the addiction of cancer to DNA repair[J]. Blood,2011,117(23):6047-6082.
[13]饶秋,周晓军.青少年肾细胞癌分子遗传学研究进展[J].医学研究生学报,2012,25(9):967-970.
[2]Jong B,Molenaar IM,Leeuw JA,et al. Cytogenetics of a renal adenocarcinoma in a 2-year-old child[J]. Cancer Genet Cytogenet,1986,21(2):165-169.
[3]朱冠辰,宋剑楠,连惠波.长期血液透析的终末期肾病患者合并肾癌二例[J].江苏医药,2015,41(5):600-601.
[4]朱文芳,何建强,巢军,等.枸橼酸?无肝素和低分子肝素抗凝在血液透析中的应用评价[J].临床医学,2015,5(35):39-41.
[5]施向东.枸橼酸抗凝在血液透析中的应用[J].中国中西医结合肾病杂志,2007,8(5):286-287.
[6]Tolwani A,Wille KM. Advances in continuous renal replacement therapy:citrate anticoagulation update[J]. Blood Purif,2012,34(2):88-93.
[7]Yamashita K,Ito F,Nakazawa H. Perioperative outcomes of laparoscopic radical nephrectmy for renal ceysis-dependent end-stsge renal disease[J]. Ther Apher Dial,2012,16(3):254-259.
[8]Argani P,Lal P,Hutchinson B,et al. Aberrant nuclear Immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions:a sensitive and specific immunohistochemical assay[J]. Am J Surg Pathol,2003,27(6):750-761.
[9]陈显成,甘卫东,郭宏骞. Xp11.2易位/TFE3基因融合相关性肾癌:一种需要更多认识的肾癌亚型[J].中华临床医师杂志(电子版),2014,8(21):3749-3752.
[10]鲁勤波,高艳青.腹膜透析和血液透析对终末期肾病患者免疫功能的对比研究[J].中国中西医结合肾病杂志,2015,16(3):249-251.
[11]Scherer A,Gunther OP,Balshaw RF,et al. Alteration of human blood cell transcriptome in uremia[J]. BMC Medical Genomics,2013,6(1):1755-1767.
[12]Shaheen M,Allen C,Nickoloff J A,et al. Synthetic lethality:exploiting the addiction of cancer to DNA repair[J]. Blood,2011,117(23):6047-6082.
[13]饶秋,周晓军.青少年肾细胞癌分子遗传学研究进展[J].医学研究生学报,2012,25(9):967-970.